News of Note—BioLineRx financing; Ablynx fast track; Ophthotech pivot; Dynavax briefing documents


> BioLineRx secured a $9.6 million investment from its largest shareholder. The Novartis-partnered biotech raised the money from BVF Partners to fund clinical development. Release

> The FDA awarded fast-track status to Ablynx’s caplacizumab in acquired thrombotic thrombocytopenic purpura. Ablynx is planning to file for FDA approval of the anti-von Willebrand factor single-domain antibody next year. The fast-track nod means caplacizumab is eligible for priority review by the regulator. Statement

> Ophthotech pivoted into rare diseases. The biotech plans to test C5 complement inhibitor Zimura in Stargardt disease. Ophthotech’s interest in testing the drug in rare diseases follows setbacks to its ambition to treat age-related retinal conditions. Release


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> The FDA has published the briefing documents for an advisory committee meeting about Dynavax’s hepatitis B vaccine. Documents (PDF)

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.